ITRM Iterum Therapeutics Plc

$ITRM at every AFC. Of course I want success for Orlynvah because of the monetary outcome for me personally but I want it more for the patients across the world that desperately need it.

$ITRM The fire sale that could have occurred back in April was always possible, since then we are 7 months in with what I deem has been a positive (not great) liquidation process, especially regarding the asset itself which is very clearly alive and well. Teneo had a head start (two confirmed interested parties) so in reality we are much further on from 7 months. I know nothing, I’m not an expert, but I did always feel this coming (ID)week was the week for some noises moreso if we have an agreement (if there were one not announcing anything would be like proposing to someone on Xmas eve and not mentioning to your families who are all gathered for Xmas dinner the next day, it would be weird). It’s starting to drag now & Teneo have to pull their finger out. I’m still confident for news in Oct, but the desire to turn to the bottle to escape this nightmare draws closer. Good luck my long suffering soldiers. Here’s to a good week 🍀

$ITRM Source: Prior authorization criteria for FEP Medicare Prescription Drug Program (MPDP Basic) under PSHB — the Postal Service Health Benefits program for USPS employees and retirees enrolled in Medicare, administered by Blue Cross Blue Shield. requirement: the infection is proven or strongly suspected to be caused by susceptible bacteria, based on either culture and susceptibility testing, OR local epidemiology and susceptibility patterns. • No prerequisite therapy required. • No age or prescriber restrictions. • Coverage duration: 14 days. Why this matters: • A culture is not mandatory — local resistance patterns are enough. • No step therapy, which is the biggest access barrier in most other formularies. • Likely continues into 2027, following an October 2026 review conducted while the company was in liquidation. Context: This is the third federal program after TRICARE and FEP commercial, all with flexible terms. Federal payers clearly view the drug favorably.

Teneo has been terrible *No meaningful progress updates on asset sales or potential acquisition discussions. * No indicative timeline for the liquidation or its anticipated conclusion. * No transparency regarding milestones achieved or remaining. * No meaningful shareholder engagement, despite significant financial losses and prolonged uncertainty. * No acknowledgment of the emotional and financial toll this silence has imposed on investors. Teneo should not prevent basic updates like any other professional liquidation company. Teneo will also be judged by how it treats shareholders throughout this process which like $ITRM has been a disaster

$ITRM looks like my previous comment was taken down: so much for keeping it real 😂. Version #2, because apparently folks can’t handle the phrase “Caulk block” 😂😳 Round 2: we’ve got a CFO, who should never have made himself CEO(CFOs are NOT CEO material), who collected 20 million in salary over 10 years. He barely managed to get a good drug over the FDA finish line post CRL. He dodges a lawsuit by winning on appeal for the complaint of making overly confident, misleading statements to shareholders that he wouldn’t get a CRL😂Despite the FDA win, he manages to drain the company of cash, take the share price to basically zero, throw the company into liquidation and FAIL TO SELL said drug- why? He takes $ that “CAULK BLOKS” his stated goal of selling the drug post FDA approval. Don’t care how challenging market is for antibiotics: this guy should NEVER be allowed near a biotech co. again- he should carry a warning label: “beware, incinerator of cash, decimator of shareholder value”.

$ITRM I actually see them both on twitter regularly, calling out teneo directly & bringing attention to things which I admire & much more valuable than complaining here - they are very much alive & deserve credit & appreciation for sticking their necks out always.

$ITRM I feel like a destitute smoker with no money searching the street floor for cast off cigerrtte butts for something, anything but alas, our friends Teneo in their ivory towers refuse to throw any of us a bone/cigerette. One cigarette butt I look to is within Shionogi’s earnings tomorrow, there will be nothing no doubt, but all I need is a little to hold off my insanity. I still have faith tho that we hear something soon (at the very least Tebeo have to provide an update in April, April! Can you imagine if we get that far). I only need $0.50ish to be happy but man I must have really annoyed God in a prior life to have deserved this punishment. Good things (better) come to those who wait

$ITRM important data presented today that makes sulopenem more attractive as a buyout candidate:

$ITRM with the way things are playing out I’m starting to suspect this won’t be over this year

$ITRM two bidders right around FDA approval. No rush to launch though. Must have been RLN max pay out demands piled on top of bids based on no real world sales numbers that chewed up more than 1 months. So they decide to go to liquidation( right around arrival of Whalen-was it his idea?) to remove teeth/negotiating power of RLNs-so what’s the reason for the 7 months? If BO was low, we’d be done months ago. So it’s either a really big number or no one wants to pay much for the uUTI indication and other uUTI markets ex US don’t pay a high price/dose. Potentiality is there but requires a lot of extra money, time and head count(sales team). If we had multiple bidder tension you’d think we would have heard something by now- starting to think things could get worse

$ITRM Asked Ai about our relief to communications from Teneo directly to the Irish High Court? Yes. There is a statutory basis for a shareholder or contributory's (that's us) to apply to the High Court concerning the liquidation. Section 631 is the provision I would focus on. It expressly allows a contributory to apply to the court concerning a question arising in the winding up. It is not limited to creditors or the liquidators themselves. This means you do not necessarily need to wait for Teneo to agree to communicate with shareholders before seeking legal relief. There is more alot more. Sections 631, 684, 687. Irish Companies Act 2014. We have righs!

$ITRM I’m starting to lose hope too but with the low debt stack and the fact that there were 2 previous offers, there should be something left for shareholders. Somebody was interested at one time and still may be looking. I want to know what the offers were. I believe we had a right to know.

$ITRM Today is 2nd anniversary of FDA approval? A lot of speculation arround this date! Still some time for "great expert" Teneo to surprise us all! 😂😂😂

$ITRM what’s the point of all these infectious disease conferences they talk about all the live saved, but it’s really a bunch of nerds getting together who may or may not have cutting edge powerful drugs but at the end of the day they’re either gatekeeping them or insurance companies are not willing to foot the bill for cutting edge new meds. What’s the point of developing these drugs and spending hundreds of millions of dollars and then you get to the point where you have FDA approved drugs that could really help people and nobody wants to use them insurance companies. Don’t want to pay for them this is most likely the last time I’ll ever invest in infectious disease drug like I said last year if this was a erectile dysfunction, we would all be millionaires.

$ITRM AI estimated a $1.03 per share payout in the unlikely scenario that someone buys Orylnvah for $100 million. -- While the math works out in your favor at a $100 million valuation, the real-world probability of this happening is extraordinarily low for several reasons: • Active U.S. Market Withdrawal: Teneo is not running an active M&A auction; they are executing a regulatory withdrawal of ORLYNVAH from the U.S. commercial market. • The Valuation Gap: Before collapsing, Iterum spent $6.5 million on a launch that only yielded $400,000 in quarterly revenue. No strategic acquirer is likely to pay nine figures for an asset with that commercial profile. • The Liquidators' Formal Stance: Teneo explicitly published that because there is "no prospect of a return to shareholders," they have legally ceased all direct communications or regular updates with equity holders. They will only revert if asset realizations unexpectedly exceed all liabilities.

$ITRM reasons for 7 months: the uUTI market in the U.S. will be a long uphill effort- will require full sales team- even though repeated use of the cheap generics is not great for the gut microbiome and builds a better super resistant pathogen. Sadly, payors, behind closed doors just care about treating patient as cheaply as possible. Also, bluejepa isn’t setting the market on fire- Orly did better in many ways- but it’s still not the market Orly would capture in cUTI, but that will require big money/trial, to get FDA approval. Rest of the world will pay lower amount per dose- so it’s a volume play overseas-no other country will pay a WAC of $3500/dose. All the potentiality is great but my fear is all these other uses will require more money invested and because it’s a liquidation, fantastic molecule or not, big pharma wants a deal in a liquidation. Hoping I’m wrong and we get a huge number. Oh yes, RLNs will fight to get as much money as possible- bad loan terms- big mistake CF-

$ITRM Now that StonkZombie has weight in, I will post since he sets the bar so low. With the Pfizer Oct 20th interest rate hike coming, Gemini Pro says the loan would need to be paid off sometime late this week due to the weekend and the banks needing time to wire the money. Waiting until Monday, Oct 19 would not give the banks enough time to receive it by the Oct 20th dead line.

$ITRM trying to balance AI’s read on why it’s taken so long, vs slowly increasing possibility no one wants it. Only approved for uUTIs, a genericized category, payors insisting on step therapy, only patents for other countries- NOT approvals there, plus those countries won’t pay WAC of $3500. So it’s a “house” with lots of potential but will require a lot of capital. cUTI step down is most profitable use case, but its early days re FDA discussions➡️approval. Guessing interested buyers saw potentiality when negotiating with CF, but they wanted a big discount. CF wanted successful multi year launch valuation; so did Sarissa. Still a gap between reality, aka what it’s worth RIGHT NOW, in liquidation, vs what it’s worth in a few years… so here we are, waiting, with little to no updates. Not selling me on skills of Teneo so far. Their fees adding up and nothing to show for it so far. So, AI says wait for Shionogi R&D day- if no mention of sulopenem- then bear case more likely.

$ITRM My UAL hit $120 today as I told you I was waiting for. Banked $65K for a 2 week spec play. I’ve told you, in times of uncertainty always play the airlines. Solid financial advice. Did we get paid yet from Clownman?

$ITRM so did the bulls stop guessing and start waiting like the rest of us? Got real quiet lately.